Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by far Lilly's fastest-growing businesses, and the company's momentum in ...